目的:比较使用与未使用抗新型冠状病毒治疗、使用与未使用激素治疗、使用与未使用抗生素治疗、使用与未使用中药治疗及接种与未接种新型冠状病毒疫苗的各型新型冠状病毒感染住院患者住院天数及治疗结局的差别;比较接种与未接种新型冠状...目的:比较使用与未使用抗新型冠状病毒治疗、使用与未使用激素治疗、使用与未使用抗生素治疗、使用与未使用中药治疗及接种与未接种新型冠状病毒疫苗的各型新型冠状病毒感染住院患者住院天数及治疗结局的差别;比较接种与未接种新型冠状病毒疫苗的新型冠状病毒感染诊断分型(轻型、中型、重型及危重型)的差别。阶段性总结新型冠状病毒感染住院患者的治疗情况及疗效分析;并促进各医院新型冠状病毒感染整体诊治水平的提高,指导康复及下一阶段可能出现高峰时的治疗。方法:回顾性收集并分析陕西省抗癫痫协会会员单位医院的其中10家医院的神经内科及神经外科在2022年12月13日~2023年1月31日期间收治的新型冠状病毒感染住院患者的临床资料,评价各型新型冠状病毒感染诊断分型中各治疗组疗效和接种疫苗对诊断分型的影响。结果:对363例患者临床资料进行统计学分析,在新型冠状病毒感染诊断分型为轻型的住院患者中,抗新型冠状病毒组与非抗新型冠状病毒组之间(P Objective: To compare the differences in the number of days of hospitalization and treatment outcomes in patients with the various diagnostic types of novel coronavirus infection with and without anti-novel coronavirus therapy, with and without hormone therapy, with and without antibiotic therapy, with and without traditional Chinese medicine, and vaccinated and unvaccinated against novel coronavirus;comparison of the diagnostic classification of novel coronavirus infections (mild, moderate, severe and critical) between those vaccinated and those not vaccinated against novel coronaviruses. We will summarize the treatment of hospitalized patients with novel coronavirus infections and analyze the therapeutic efficacy in a staged manner, and promote the improvement of the overall diagnosis and treatment of novel coronavirus infections in hospitals to guide the rehabilitation and the treatment of novel coronavirus infections in the next stage, when the peak may occur. Methods: Retrospective collection and analysis of clinical data of patients hospitalized with novel coronavirus infections admitted to the Department of Neurology and Department of Neurosurgery of 10 of the hospitals that are members of the Shaanxi Provincial Anti-Epilepsy Association during the period of December 13, 2022~January 31, 2023, to evaluate the efficacy of treatment groups in the diagnostic typing of novel coronavirus infections of each type and the effect of vaccination on the diagnostic typing. Results: The clinical data of 363 patients were statistically analyzed. Among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, there were statistically significant differences in hospital days between the anti-novel coronavirus group and the non-anti-novel coronavirus group (P < 0.001) and between the hormone group and the non-hormone group (P = 0.006). There was a statistically significant difference in hospital days between the antibiotic group and the non-antibiotic group among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, moderate and severe (P < 0.001, P = 0.005, P = 0.045), and between-group variability in treatment outcomes between the vaccine and non-vaccine groups among hospitalized patients whose diagnostic typology of novel coronavirus infection was medium (P = 0.024);the likelihood of a diagnosis of critical illness was higher in the non-vaccine than in the vaccine group, relative to the mild type (OR = 11.463, 95% CI 1.352~97.186, P = 0.025). Conclusions: The application of anti-novel coronavirus therapy, hormone therapy and antibiotic therapy may increase hospital days in hospitalized patients with a diagnostic classification of mild forms of novel coronavirus infection, and the application of antibiotic therapy in hospitalized patients with a diagnostic classification of moderate and severe forms of novel coronavirus infection;the vaccine group of hospitalized patients with a diagnostic classification of moderate forms of novel coronavirus infection was more likely to have a positive outcome of the treatment, relative to the control group. Vaccination may have a positive effect on preventing progression to critical type after COVID-19 infection.展开更多
脊髓亚急性联合变性（（Subacute combined degeneration of the spinal cord,SCD）早期症状隐匿,常以疾病损害的先后部位及轻重程度不同而有所不同,过去很多病例因症状不典型,临床上造成误诊,延误治疗。现将我院2004年1月至2010年12月...脊髓亚急性联合变性（（Subacute combined degeneration of the spinal cord,SCD）早期症状隐匿,常以疾病损害的先后部位及轻重程度不同而有所不同,过去很多病例因症状不典型,临床上造成误诊,延误治疗。现将我院2004年1月至2010年12月间收治的38例SCD患者的临床、实验室、影像学、电生理检查结果进行探讨分析，为早期临床诊断、治疗及病情转归的评价提供依据。展开更多
文摘目的:比较使用与未使用抗新型冠状病毒治疗、使用与未使用激素治疗、使用与未使用抗生素治疗、使用与未使用中药治疗及接种与未接种新型冠状病毒疫苗的各型新型冠状病毒感染住院患者住院天数及治疗结局的差别;比较接种与未接种新型冠状病毒疫苗的新型冠状病毒感染诊断分型(轻型、中型、重型及危重型)的差别。阶段性总结新型冠状病毒感染住院患者的治疗情况及疗效分析;并促进各医院新型冠状病毒感染整体诊治水平的提高,指导康复及下一阶段可能出现高峰时的治疗。方法:回顾性收集并分析陕西省抗癫痫协会会员单位医院的其中10家医院的神经内科及神经外科在2022年12月13日~2023年1月31日期间收治的新型冠状病毒感染住院患者的临床资料,评价各型新型冠状病毒感染诊断分型中各治疗组疗效和接种疫苗对诊断分型的影响。结果:对363例患者临床资料进行统计学分析,在新型冠状病毒感染诊断分型为轻型的住院患者中,抗新型冠状病毒组与非抗新型冠状病毒组之间(P Objective: To compare the differences in the number of days of hospitalization and treatment outcomes in patients with the various diagnostic types of novel coronavirus infection with and without anti-novel coronavirus therapy, with and without hormone therapy, with and without antibiotic therapy, with and without traditional Chinese medicine, and vaccinated and unvaccinated against novel coronavirus;comparison of the diagnostic classification of novel coronavirus infections (mild, moderate, severe and critical) between those vaccinated and those not vaccinated against novel coronaviruses. We will summarize the treatment of hospitalized patients with novel coronavirus infections and analyze the therapeutic efficacy in a staged manner, and promote the improvement of the overall diagnosis and treatment of novel coronavirus infections in hospitals to guide the rehabilitation and the treatment of novel coronavirus infections in the next stage, when the peak may occur. Methods: Retrospective collection and analysis of clinical data of patients hospitalized with novel coronavirus infections admitted to the Department of Neurology and Department of Neurosurgery of 10 of the hospitals that are members of the Shaanxi Provincial Anti-Epilepsy Association during the period of December 13, 2022~January 31, 2023, to evaluate the efficacy of treatment groups in the diagnostic typing of novel coronavirus infections of each type and the effect of vaccination on the diagnostic typing. Results: The clinical data of 363 patients were statistically analyzed. Among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, there were statistically significant differences in hospital days between the anti-novel coronavirus group and the non-anti-novel coronavirus group (P < 0.001) and between the hormone group and the non-hormone group (P = 0.006). There was a statistically significant difference in hospital days between the antibiotic group and the non-antibiotic group among the hospitalized patients whose diagnostic classification of novel coronavirus infection was mild, moderate and severe (P < 0.001, P = 0.005, P = 0.045), and between-group variability in treatment outcomes between the vaccine and non-vaccine groups among hospitalized patients whose diagnostic typology of novel coronavirus infection was medium (P = 0.024);the likelihood of a diagnosis of critical illness was higher in the non-vaccine than in the vaccine group, relative to the mild type (OR = 11.463, 95% CI 1.352~97.186, P = 0.025). Conclusions: The application of anti-novel coronavirus therapy, hormone therapy and antibiotic therapy may increase hospital days in hospitalized patients with a diagnostic classification of mild forms of novel coronavirus infection, and the application of antibiotic therapy in hospitalized patients with a diagnostic classification of moderate and severe forms of novel coronavirus infection;the vaccine group of hospitalized patients with a diagnostic classification of moderate forms of novel coronavirus infection was more likely to have a positive outcome of the treatment, relative to the control group. Vaccination may have a positive effect on preventing progression to critical type after COVID-19 infection.
文摘脊髓亚急性联合变性（（Subacute combined degeneration of the spinal cord,SCD）早期症状隐匿,常以疾病损害的先后部位及轻重程度不同而有所不同,过去很多病例因症状不典型,临床上造成误诊,延误治疗。现将我院2004年1月至2010年12月间收治的38例SCD患者的临床、实验室、影像学、电生理检查结果进行探讨分析，为早期临床诊断、治疗及病情转归的评价提供依据。
文摘目的:探讨注射用鼠神经生长因子联合奥拉西坦治疗高血压脑出血(hypertensive cerebral hemorrhage,HCH)的临床效果。方法:选取2017年10月至2019年1月朝阳市第二医院收治的HCH患者92例,采用简单随机数字表法将其分为观察组(n=46)和对照组(n=46)。对照组患者给予奥拉西坦治疗,观察组患者在此基础上加用注射用鼠神经生长因子辅助治疗,两组患者均治疗21 d。治疗结束后,对两组患者的临床疗效进行评估;并于治疗前后测评两组患者神经功能缺损程度及日常生活活动能力,检测血清脑损伤生物标志物、炎症因子及氧化应激指标水平;同时观察两组患者用药期间不良反应发生情况。结果:观察组患者的总有效率为93.48%(43/46),与对照组的76.09%(35/46)相比明显升高,差异有统计学意义(P<0.05)。两组患者治疗后美国国立卫生院卒中神经功能缺损评分量表(national institutes of health stroke scale,NIHSS)评分均较治疗前明显降低,Barthel指数(BI)评分明显升高;治疗后,观察组患者NIHSS评分较对照组同期明显更低,而BI评分明显更高,差异均有统计学意义(P<0.05)。两组患者治疗后血清脑损伤标志物(神经元特异性烯醇化酶、S100β蛋白)及相关炎症因子(白细胞介素8、肿瘤坏死因子α及超敏C反应蛋白)水平均较治疗前明显降低(P<0.05),而观察组患者降低更显著,差异均有统计学意义(P<0.05)。两组患者治疗后血清超氧化物歧化酶(SOD)水平均较治疗前明显升高,血清丙二醛(MDA)、脂质过氧化物(LPO)含量明显降低;且治疗后,观察组患者血清SOD水平明显高于对照组同期,血清MDA、LPO含量则明显更低,差异均有统计学意义(P<0.05)。观察组患者不良反应发生率为15.22%(7/46),与对照组的17.39%(8/46)比较,差异无统计学意义(P>0.05)。结论:注射用鼠神经生长因子联合奥拉西坦治疗HCH可能通过下调患者相关炎症因子表达水平、纠正机体氧化应激的途径来保护脑组织,促进受损神经功能的恢复,整体疗效显著,且患者耐受性较好。
